Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06706622 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Study acronym: MASCOT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv18
  2. Trial arms changed: 3 → 2 Study description shortened, about 7 words · Study sites revised (74)v17 Show 2 more changesShow less
    • Study description shortened, about 7 words
    • Study sites revised (74)

    See this version in full on ClinicalTrials.gov ↗

  3. Enrollment increased: 357 → 401 participants Study sites revised (74)v16 Show 1 more changeShow less
    • Study sites revised (74)

    See this version in full on ClinicalTrials.gov ↗

  4. Enrollment target: estimated 360 to confirmed 357v15
  5. Trial status: Recruiting to Active, Not Recruiting Study sites: 73 to 74v14 Show 1 more changeShow less
    • Study sites: 73 to 74
Show 12 earlier versionsHide 12 earlier versions
  1. Primary endpoints revised (2) Interventions: Lu AF82422 (Drug), Placebo (Drug) to Amlenetug (Drug), Placebo (Drug) · Secondary endpoints: 21 to 27 · Eligibility criteria expanded, about 2 words · 2 morev13 Show 5 more changesShow less
    • Interventions: Lu AF82422 (Drug), Placebo (Drug) to Amlenetug (Drug), Placebo (Drug)
    • Secondary endpoints: 21 to 27
    • Eligibility criteria expanded, about 2 words
    • Study description expanded, about 3 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 70 to 73v12
  3. Study sites: 66 to 70v11
  4. Study sites: 63 to 66v10
  5. Study sites: 58 to 63v9
  6. Study sites: 42 to 58v8
  7. Study sites: 29 to 42v7
  8. Study sites: 17 to 29v6
  9. Study sites: 7 to 17v5
  10. Study sites: 4 to 7v4
  11. Study sites: 3 to 4v3
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3v2 Show 1 more changeShow less
    • Study sites: 0 to 3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
H. Lundbeck A/S
20 trials monitored
See 1 trial at risk
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
Trial Details
NCT Number NCT06706622
Lead Sponsor H. Lundbeck A/S
Conditions Multiple System Atrophy
Enrollment 401 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov